FDA Links

FDA Logo
    Visit Us on FacebookVisit Us on TwitterVisit Us on YouTubeSign up for email updatesVisit Us on Flickr
Food and Drug Association Links 

Cannabinoids as antioxidants and neuroprotectants 
US 6630507 B1
Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH3, and COCH3.

Publication numberUS6630507 B1
Publication typeGrant
Application numberUS 09/674,028
PCT numberPCT/US1999/008769
Publication dateOct 7, 2003
Filing dateApr 21, 1999
Priority dateApr 21, 1998
Fee statusPaid
Also published asCA2329626A14 More »
InventorsAidan J. HampsonJulius AxelrodMaurizio Grimaldi
Original AssigneeThe United States Of America As Represented By The Department Of Health And Human Services
Export CitationBiBTeXEndNoteRefMan

YouTube Video

‪#‎CBD‬ Drugs, Money... Stock buy? The validation of CBD? A good read on Orphan drug status... The designation provides the drug developer with a seven-year period of U.S. marketing exclusivity upon approval, as well as certain financial incentives that can help support its development. 99.5% pure CBD. So here is how it rolls...  To do research with Cannabis in the United States, researchers must file an Investigational New Drug (IND) application with the Food and Drug Administration (FDA), receive a Schedule I license from the Drug Enforcement Administration (DEA), and gain approval from the National Institute on Drug Abuse (NIDA).#1 The Health and Human resources owns the patent on Cannabinoids. CBD is one cannabinoid. #2 The NIH "National Institute of Health" works the financials between our Govt and the drug company. #3 The FDA "Food and Drug Administration" Covers the health and benefit concerns. YES this is a good thing folks! For me it means that we have the Government of the United States and a publicly traded company validating CBD. I get folks who will ask me Scott how can we trust you on suggesting CBD will help with blah... I always state I can't recommend or suggest anything about CBD, not legal to do. However the facts are presented by the Health and Human resources the National Institute of Health The FDA and several Drug companies including GW Pharmaceutical and Insys Therapeutics that afford us a clearer view into their idea of CBD and how it could work. I can tell you about form factor to the intake method and form factor to the CBD present in the form factor. I can tell you about publicly traded companies who make CBD too. To recommend or suggest? no can do! Again... Good thing the Gov't of The United States is controlling the release of CBD from Cannabis/Marijuana. The companies we represent in reselling CBD come from Cannabis/imported industrialized hemp plants. 

Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol for the Treatment of Infantile Spasms